InspireMD 5/14/2024 Earnings Report

InspireMD EPS Results

• Actual EPS: -$0.21
• Consensus EPS: -$0.15
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: -$0.53

InspireMD Revenue Results

• Actual Revenue: $1.51 million
• Expected Revenue: $1.38 million
• Beat/Miss: Beat by +$130.00 thousand
• YoY Revenue Growth: N/A

InspireMD Announcement Details

• Date: 5/14/2024
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

InspireMD (NYSE:NSPR) is a medical device company focused on developing and commercializing next-generation implantable devices to prevent embolic stroke in patients undergoing vascular interventions. The company’s flagship technology, the CGuard™ Embolic Prevention System (EPS), integrates MicroNET™ mesh technology with a self-expanding nitinol stent. This design aims to capture and contain plaque and embolic debris at the treatment site, reducing the risk of downstream complications during and after carotid artery procedures.

The CGuard EPS is indicated for use in patients with carotid artery stenosis at risk of stroke and is designed to be delivered via a minimally invasive percutaneous approach. The MicroNET mesh covering provides enhanced vessel conformability and has demonstrated promising clinical results in reducing peri-procedural embolic events. In addition to its carotid applications, InspireMD is actively exploring the potential of MicroNET technology in treating intracranial atherosclerotic disease, with ongoing studies examining safety and efficacy profiles in diverse vascular territories.

Founded in 2002 and headquartered in Tel Aviv, Israel, InspireMD operates in key markets worldwide, including Europe, the United States, Latin America and select countries in Asia. The company has secured CE Mark approval for CGuard in the European Union and received Premarket Approval (PMA) from the U.S. Food and Drug Administration. InspireMD’s commercial strategy combines direct sales in core markets with distribution partnerships to extend its global reach, supported by physician training programs and real-world data collection initiatives.

InspireMD is led by a management team with extensive experience in interventional cardiology, neurology and medical technology commercialization. The company’s board of directors and scientific advisors include recognized experts in vascular intervention, stroke prevention and regulatory affairs. InspireMD continues to pursue innovative research collaborations and clinical trials aimed at expanding the applications of its MicroNET technology to address unmet needs in vascular medicine.